Weiss Ratings Reaffirms Sell (D-) Rating for Omeros (NASDAQ:OMER)

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Omeros (NASDAQ:OMER), indicating cautious sentiment from this ratings agency.
• Omeros's stock has received mixed ratings from various analysts, with target prices ranging from $9.00 to $45.00, and currently has a consensus rating of "Moderate Buy" with a target price of $27.50.
• Recent trading activity shows Omeros stock at $7.55, after hitting a 1-year low of $2.95 and a high of $13.60, reflecting significant volatility in its market performance.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

OMER has been the topic of a number of other reports. HC Wainwright upped their target price on shares of Omeros from $9.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, October 15th. WBB Securities restated a "strong-buy" rating and set a $45.00 target price on shares of Omeros in a research report on Wednesday, October 15th. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Wednesday, October 15th. Wall Street Zen upgraded shares of Omeros from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th. Finally, D. Boral Capital restated a "buy" rating and set a $36.00 price objective on shares of Omeros in a report on Wednesday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.50.

Omeros Trading Down 1.3%

Omeros stock opened at $7.55 on Friday. Omeros has a 1 year low of $2.95 and a 1 year high of $13.60. The company has a market cap of $513.85 million, a PE ratio of -3.58 and a beta of 2.32. The company's 50-day moving average is $4.93 and its two-hundred day moving average is $4.56.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. The business had revenue of $28.60 million for the quarter, compared to analyst estimates of $0.31 million. Research analysts forecast that Omeros will post -3.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OMER. Wealth Enhancement Advisory Services LLC bought a new position in Omeros in the first quarter valued at approximately $579,000. Hsbc Holdings PLC bought a new position in Omeros in the first quarter valued at approximately $142,000. Nuveen LLC bought a new position in Omeros in the first quarter valued at approximately $938,000. Wellington Management Group LLP bought a new position in Omeros in the first quarter valued at approximately $1,118,000. Finally, Invesco Ltd. lifted its stake in Omeros by 169.1% in the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company's stock valued at $716,000 after buying an additional 54,696 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.